Search Result

Pathways Recommended:	Stem Cell/Wnt Cell Cycle/DNA Damage

Results for "

cell chemotaxis

" in MedChemExpress (MCE) Product Catalog:

By Targets:	5-HT Receptor (2) Akt (1) Angiotensin Receptor (4) Apoptosis (4) Bacterial (3) Biochemical Assay Reagents (1) c-Kit (1) Calcium Channel (2) CCR (13) CXCR (4) DOCK (1) Drug Derivative (1) Endogenous Metabolite (5) Formyl Peptide Receptor (FPR) (6) G Protein-coupled Receptor Kinase (GRK) (1) GPR84 (2) Histamine Receptor (3) HuR (1) Isotope-Labeled Compounds (4) Leukotriene Receptor (1) Ligands for Target Protein for PROTAC (1) mRNA (7) NF-κB (2) P-selectin (1) Phospholipase (2) PI3K (1) Platelet-activating Factor Receptor (PAFR) (2) Reference Standards (5) RET (1) VEGFR (1)
By Research Areas:	Cancer (16) Cardiovascular Disease (6) Endocrinology (7) Infection (5) Inflammation/Immunology (30) Metabolic Disease (3) Neurological Disease (10)
Oligonucleotides:	Chemokine & Receptors (3) Phospholipids (1) mRNA (7)

Inhibitors & Agonists

Biochemical Assay Reagents

Peptides

Inhibitory Antibodies

Natural
Products

Isotope-Labeled Compounds

Oligonucleotides

Targets Recommended: Programmed Cell Death 4 (PDCD4) Itk TOPK NAMPT ALCAM/CD166 GDNF Receptor BCL6 Tim3 VISTA BMI1

Cat. No.	Product Name	Target	Research Areas	Chemical Structure

HY-B0202

Irbesartan Maximum Cited Publications 8 Publications Verification SR-47436; BMS-186295	Angiotensin Receptor Apoptosis	Cardiovascular Disease Endocrinology
Irbesartan (SR-47436) is an orally active Ang II type 1 (AT1) receptor blocker (ARB). Irbesartan can relax the blood vessels, low blood pressure and increase the supply of blood and oxygen to the heart. Irbesartan can be used for the research of high blood pressure, heart failure, and diabetic kidney disease .

HY-12807

FIPI 5 Publications Verification 5-Fluoro-2-indolyl deschlorohalopemide	Phospholipase	Cardiovascular Disease Neurological Disease Inflammation/Immunology Cancer
FIPI is a phospholipase D (PLD) inhibitor with an IC₅₀ for PLD1 and PLD2 of about 25 nM. FIPI regulates cytoskeletal recombination, cell diffusion and chemotaxis. FIPI can be used in cancer research. In addition, FIPI can enhance the secretion and aggregation of platelet dense particles, inhibit thrombosis, reduce ischemic stroke infarct volume and improve nerve function .

HY-P4744

LL-37 amide 2 Publications Verification	Formyl Peptide Receptor (FPR) Bacterial	Infection Cancer
LL-37 amide is a selective agonist of formyl peptide receptor-like FPRL1, effectively inhibiting periodontal pathogens (ED₉₉=8.5-8.7 μg/mL). LL-37 amide exerts its bactericidal effect by activating FPRL1-mediated immune cell chemotaxis and disrupting bacterial cell membrane integrity. It can also regulate inflammatory responses (inhibiting the release of factors such as TNF-α) and promote angiogenesis. Amidation modification reduces its sensitivity to serum inhibition and improves its stability. LL-37 amide possesses key activities in bactericidal action, immunomodulation, and wound healing, and is mainly used in research on infection-related diseases such as periodontal disease and deep tissue injuries (pressure ulcers), and wound healing .

HY-B2176R

ATP (Standard) Adenosine 5'-triphosphate (Standard)	Reference Standards Endogenous Metabolite	Metabolic Disease Inflammation/Immunology
ATP (Standard) is the analytical standard of ATP. This product is intended for research and analytical applications. ATP (Adenosine 5'-triphosphate) is a central component of energy storage and metabolism in vivo. ATP provides the metabolic energy to drive metabolic pumps and serves as a coenzyme in cells. ATP is an important endogenous signaling molecule in immunity and inflammation . In Vitro: ATP (5 mM; 1 hour) co-treatment with LPS (1 μg/mL) has a synergistic effect on the activation of the NLRP3 inflammasome in HGFs . ATP (2 mM; 0.5-24 hours) induces secretion of IL-1β, KC and MIP-2 from BMDMs in a caspase-1 activation-dependent manner . ATP promotes neutrophil chemotaxis in vitro . In Vivo: ATP (50 mg/kg; i.p.) protects mice against bacterial infection in vivo . ATP induces the secretion of IL-1β, KC and MIP-2 and neutrophils recruitment in vivo .

HY-W127575

Cholesta-3,5-diene delta-3,5-Cholestadiene	PI3K Akt	Inflammation/Immunology
Cholesta-3,5-diene is an inflammatory modulator that targets immune cells such as neutrophils and accelerates wound healing by promoting neutrophil chemotaxis and fibroblast migration. Cholesta-3,5-diene enhances immune cell recruitment and extracellular matrix deposition by activating chemokine receptor-mediated signaling pathways such as PI3K/Akt. Cholesta-3,5-diene can be applied topically to wound repair and has potential therapeutic value in chronic ulcers or skin lesions .

HY-15724

Vercirnon 3 Publications Verification GSK-1605786; CCX282-B; Traficet-EN	CCR Ligands for Target Protein for PROTAC	Inflammation/Immunology Endocrinology
Vercirnon (GSK1605786A) is an orally bioavailable, selective, and potent antagonist of CCR9. Vercirnon inhibits CCR9-mediated Ca ²⁺ mobilization and chemotaxis on Molt-4 cells with IC₅₀ values of 5.4 and 3.4 nM, respectively. Vercirnon is selective for CCR9 over CCR1-12 and CX3CR1-7 (IC₅₀s>10 μM for all). Vercirnon is an equipotent inhibitor of CCL25-directed chemotaxis of both splice forms of CCR9 (CCR9A and CCR9B) with IC₅₀ values of 2.8 and 2.6 nM, respectively .

HY-148853

SRI-42127 1 Publications Verification	HuR	Others
SRI-42127 is a HuR translocation inhibitor. HuR is an RNA regulator that binds to AREs, and HuR translocations promote the production of inflammatory cytokines in glial cells. However, SRI-42127 can destroy mRNA stability and inhibit gene promoter activation. SRI-42127 also inhibits microglial cell activation and attenuates recruitment/chemotaxis of neutrophils and monocytes .

HY-N0634

Cimifugin 1 Publications Verification Cimitin	NF-κB	Inflammation/Immunology
Cimifugin (Cimitin) is a bioactive component of Cimicifuga racemosa, a Chinese herb. Cimifugin suppresses allergic inflammation by reducing epithelial derived initiative key factors via regulating tight junctions . Cimifugin reduces the migration and chemotaxis of RAW264.7 cells and inhibits the release of inflammatory factors and activation of MAPKs and NF-κB signaling pathways induced by LPS .

HY-153128

DOCK2-IN-1	DOCK Drug Derivative	Inflammation/Immunology
DOCK2-IN-1 (Compound 3) is an analog of CPYPP (HY-110100) and a DOCK2 inhibitor (IC₅₀ = 19.1 μM). DOCK2-IN-1 binds to the DHR-2 domain of DOCK2 and inhibits its mediated Rac guanine nucleotide exchange factor activity. DOCK2-IN-1 blocks chemokine receptor- and antigen receptor-mediated activation of Rac in lymphocytes. DOCK2-IN-1 significantly inhibits chemotaxis and T cell activation. DOCK2-IN-1 can be used in the research of transplant rejection and organ-specific autoimmune diseases .

HY-P991567

VX5 VX5/5261	CXCR	Inflammation/Immunology Cancer
VX5 (VX5/5261) is a humanized IgG1κ monoclonal antibody inhibitor targeting BCA-1/CXCL13. VX5 significantly inhibits human CXCL13-mediated internalization of CXCR5, blocks both human and mouse CXCL13-dependent B-cells chemotaxis and migration. VX5 can be used to study autoimmune diseases like multiple sclerosis and arthritis, and cancers like gastric lymphomas and colon cancer .

HY-P10724

fMIFL	Formyl Peptide Receptor (FPR) Bacterial	Infection
fMIFL is a formyl tetrapeptide derived from Staphylococcus aureus, and also an agonist of mouse formyl peptide receptor 1 (mFPR1). It exhibits nanomolar activity against mFPR1 and micromolar activity against mFPR2. fMIFL is applicable to studies related to bacterial infections .

HY-124416

ML604086 1 Publications Verification	CCR	Inflammation/Immunology Endocrinology
ML604086 is a selective CCR8 inhibitor, inhibiting CCL1 binding to CCR8 on circulating T-cells. ML604086 inhibits CCL1 mediated chemotaxis and increases in intracellular Ca ²⁺ concentrations .

HY-123532

JNJ10191584 VUF6002	Histamine Receptor	Neurological Disease
JNJ10191584 (VUF6002) is an orally active and selective histamine H₄ receptor antagonist with a K_i value of 26 nM. JNJ10191584 shows 540-fold selectivity to H₄ receptor over H₃ receptor with a K_i value of 14.1 μM. JNJ10191584 inhibits chemotaxis of eosinophils and mast cells with IC₅₀ values of 530 nM and 138 nM, respectively .

HY-P4744A

LL-37 amide TFA 2 Publications Verification	Formyl Peptide Receptor (FPR) Bacterial	Infection Cancer
LL-37 amide TFA is a selective agonist of formyl peptide receptor-like FPRL1, effectively inhibiting periodontal pathogens (ED₉₉=8.5-8.7 μg/mL). LL-37 amide TFA exerts its bactericidal effect by activating FPRL1-mediated immune cell chemotaxis and disrupting bacterial cell membrane integrity. It can also regulate inflammatory responses (inhibiting the release of factors such as TNF-α) and promote angiogenesis. Amidation modification reduces its sensitivity to serum inhibition and improves its stability. LL-37 amide TFA possesses key activities in bactericidal action, immunomodulation, and wound healing, and is mainly used in research on infection-related diseases such as periodontal disease and deep tissue injuries (pressure ulcers), and wound healing .

HY-P99443

Aselizumab HuDreg-55	P-selectin	Inflammation/Immunology
Aselizumab (HuDreg-55) is an humanized IgG4 mAb against L-selectin. However, L-selectin (CD62L) is a cell adhesion molecule expressed on circulating neutrophils. It regulates migrating cells to chemotaxis towards the site of injury. Aselizumab may be account for a high rate of infections and leucopenia after truma .

HY-15724A

Vercirnon sodium 3 Publications Verification GSK-1605786 sodium; CCX282-B sodium; Traficet-EN sodium	CCR	Inflammation/Immunology Endocrinology
Vercirnon (GSK1605786A) sodium is an orally bioavailable, selective, and potent antagonist of CCR9. Vercirnon sodium inhibits CCR9-mediated Ca ²⁺ mobilization and chemotaxis on Molt-4 cells with IC₅₀ values of 5.4 and 3.4 nM, respectively. Vercirnon sodium is selective for CCR9 over CCR1-12 and CX3CR1-7 (IC₅₀s>10 μM for all). Vercirnon sodium is an equipotent inhibitor of CCL25-directed chemotaxis of both splice forms of CCR9 (CCR9A and CCR9B) with IC₅₀ values of 2.8 and 2.6 nM, respectively .

HY-116116

Tafetinib SIM010603	c-Kit RET VEGFR	Cancer
Tafetinib (SIM010603) is an oral multi-targets receptor tyrosine kinases inhibitor. Tafetinib inhibitsstem cell factor receptor (Kit),vascular endothelial growth factor receptor-2 (VEGFR-2),platelet-derived growth factor receptor-β (PDGFR-β),*glial cell* line-derived neurotrophic factor receptor (Rearranged during Transfection; RET)*, andFms-like tyrosine kinase-3 (FLT3)withIC₅₀values between 5.0 and 68.1 nmol/l. Tafetinib inhibits the phosphorylation ofPDGFR-βandVEGFR-2. Tafetinib inhibits endothelial cell* proliferation, endothelial cells chemotaxis, and corneal angiogenesis .

HY-126346

DL-175	GPR84	Inflammation/Immunology
DL-175 (compound 13) is a selective GPR84 agonist with biased agonistic activity. DL-175 can selectively activate functional responses in immune cells and induce enhanced chemotaxis and phagocytosis of human bone marrow cells. DL-175 is a potential chemical probe .

HY-103472

FPR-A14 1 Publications Verification	Formyl Peptide Receptor (FPR)	Neurological Disease
FPR-A14 is a potent formyl peptide receptor (FPR) agonist. FPR-A14 is a potent activator of neutrophil Ca ²⁺ mobilization and chemotaxis with EC₅₀s of 630 nM and 42 nM, respectively. FPR-A14 induces cell differentiation .

HY-W345359

PAF C-18:1	Endogenous Metabolite	Inflammation/Immunology
PAF C-18:1 is a naturally occurring phospholipid produced by cells upon inflammatory responses. PAF C-18:1 is a chemoattractant, and induces human neutrophil chemotaxis .

HY-155300

BLT2 antagonist-1	Leukotriene Receptor	Inflammation/Immunology
BLT2 antagonist-1 (compound 15b) is a selective BLT2 antagonist that inhibits the chemotaxis of CHO-BLT2 cells with an IC₅₀ of 224 nM. BLT2 antagonist-1 does not inhibits the chemotaxis of CHO-BLT1 cells. BLT2 antagonist-1 also inhibits the binding of LTB4 and BLT2 with a K_i value of 132 nM. BLT2 antagonist-1 can be used for the research of the inflammatory airway diseases such as asthma and chronic obstructive pulmonary disease .

HY-107558

JNJ10191584 maleate VUF6002 maleate	Histamine Receptor	Neurological Disease
JNJ10191584 (VUF6002) maleate (compound 40) is an orally active and selective histamine H₄ receptor antagonist with a K_i value of 26 nM. JNJ10191584 maleate shows 540-fold selectivity to H₄ receptor over the H₃ receptor with a K_i value of 14.1 μM. JNJ10191584 maleate inhibits chemotaxis of eosinophils and mast cells with IC₅₀ values of 530 nM and 138 nM, respectively .

HY-174761

Human CCL21 mRNA	mRNA	Inflammation/Immunology
Human CCL21 mRNA encodes the human C-C motif chemokine ligand 21 (CCL21) protein, a chemokine that can inhibit hemopoiesis and stimulate chemotaxis. CCL21 is chemotactic in vitro for thymocytes and activated T cells, but not for B cells, macrophages, or neutrophils. It may also play a role in mediating homing of lymphocytes to secondary lymphoid organs.

HY-P11553

ECL1i	CCR	Inflammation/Immunology
ECL1i is an allosteric, selective CCR2 inhibitor. ECL1i specifically inhibits CCL2-/CCR2-mediated chemotaxis. ECL1i interferes with CCR2-positive cell recruitment and attenuates disease progression in experimental autoimmune encephalomyelitis .

HY-P11553A

ECL1i TFA	CCR	Infection Inflammation/Immunology
ECL1i TFA is an allosteric, selective CCR2 inhibitor. ECL1i TFA specifically inhibits CCL2-/CCR2-mediated chemotaxis. ECL1i TFA interferes with CCR2-positive cell recruitment and attenuates disease progression in experimental autoimmune encephalomyelitis .

HY-P1121

WKYMVM-NH2	Formyl Peptide Receptor (FPR)	Inflammation/Immunology
WKYMVM-NH2 is a hexapeptide that activates neutrophils and myeloid cells via the FPRL1 and FPRL2 receptors. It exhibits EC₅₀ values of 2 nM and 80 nM in HL-60-FPRL1 and HL-60-FPRL2 cells, respectively. In HL-60 cells stably expressing FPRL2, WKYMVM-NH₂ induces chemotaxis, with optimal migration observed at concentrations ranging from 10 to 50 nM. It also stimulates superoxide production in neutrophils, with an EC₅₀ of 75 nM. WKYMVM-NH₂ is a useful tool for research in the field of inflammatory diseases .

HY-W783254

C18 LPA PA(18:0e/0:0)	G Protein-coupled Receptor Kinase (GRK) Calcium Channel	Cardiovascular Disease Cancer
C18 LPA (PA(18:0e/0:0)) is a water-soluble phospholipid that functions as a signaling molecule, influencing various cellular responses through G protein-coupled receptors (GPCRs). It is known to promote smooth muscle contraction, cytoskeletal rearrangement, and chemotaxis, while also playing a role in neurotransmitter release, cell proliferation, platelet aggregation, and Ca2+ mobilization. Elevated levels of C18 LPA in human plasma are associated with ovarian cancer and atherosclerosis, suggesting its potential as a biomarker for ovarian cancer.

HY-B0202A

Irbesartan hydrochloride SR-47436 hydrochloride; BMS-186295 hydrochloride	Angiotensin Receptor Apoptosis	Cardiovascular Disease Neurological Disease Metabolic Disease
Irbesartan (SR-47436) hydrochloride is an orally active Ang II type 1 (AT1) receptor blocker (ARB). Irbesartan hydrochloride can relax the blood vessels, low blood pressure and increase the supply of blood and oxygen to the heart. Irbesartan hydrochloride can be used for the research of high blood pressure, heart failure, and diabetic kidney disease .

HY-12807A

FIPI hydrochloride 5-Fluoro-2-indolyl deschlorohalopemide hydrochloride	Phospholipase	Cardiovascular Disease Neurological Disease Inflammation/Immunology Cancer
FIPI hydrochloride is a phospholipase D (PLD) inhibitor with an IC₅₀ for PLD1 and PLD2 of about 25 nM. FIPI hydrochloride regulates cytoskeletal recombination, cell diffusion and chemotaxis. FIPI hydrochloride can be used in cancer research. In addition, FIPI hydrochloride can enhance the secretion and aggregation of platelet dense particles, inhibit thrombosis, reduce ischemic stroke infarct volume and improve nerve function .

HY-123270

RP23618	CCR	Infection Inflammation/Immunology
RP23618 is a non peptidic RANTES antagonist with the IC₅₀ of 3 μM. RP23618 inhibit RANTES-induced chemotaxis of THP-1 cells .

HY-174553

Human PDGFA mRNA	mRNA	Cancer
Human PDGFA mRNA encodes the human platelet derived growth factor A (PDGFA) protein, a member of the platelet-derived growth factor family. PDGFA plays an essential role in the regulation of embryonic development, cell proliferation, cell migration, survival and chemotaxis.

HY-174552

Human PDGFB mRNA	mRNA	Cancer
Human PDGFB mRNA encodes the human platelet derived growth factor B (PDGFB) protein, a member of the platelet-derived growth factor family. PDGFB plays an essential role in the regulation of embryonic development, cell proliferation, cell migration, survival and chemotaxis.

HY-174550

Human PDGFD mRNA	mRNA	Cancer
Human PDGFD mRNA encodes the human platelet derived growth factor D (PDGFD) protein, a member of the platelet-derived growth factor family. PDGFD plays an essential role in the regulation of embryonic development, cell proliferation, cell migration, survival and chemotaxis.

HY-174551

Human PDGFC mRNA	mRNA	Cancer
Human PDGFC mRNA encodes the human platelet derived growth factor C (PDGFC) protein, a member of the platelet-derived growth factor family. PDGFC plays an essential role in the regulation of embryonic development, cell proliferation, cell migration, survival and chemotaxis.

HY-174752

Human CCL4L1 mRNA	mRNA	Inflammation/Immunology
Human CCL4L1 mRNA encodes the human C-C motif chemokine ligand 4 like 1 (CCL4L1) protein, a chemokine that can induce chemotaxis of cells expressing CCR5 or CCR1.

HY-174741

Human CCR8 mRNA	mRNA	Inflammation/Immunology
Human CCR8 mRNA encodes the human C-C motif chemokine receptor 8 (CCR8) protein, a member of the beta chemokine receptor family. CCR8 plays a role in regulation of monocyte chemotaxis and thymic cell apoptosis. More specifically, this receptor may contribute to the proper positioning of activated T cells within the antigenic challenge sites and specialized areas of lymphoid tissues.

HY-119234

CX4338	CXCR	Inflammation/Immunology
CX4338 is a CXCL8-mediated chemokine inhibitor with the activity of inhibiting CXCR2-mediated cell migration. CX4338 selectively inhibits CXCR2-mediated β-arrestin-2 recruitment and receptor internalization while enhancing CXCR2-mediated MAPK activation. CX4338 also inhibited CXCL8-induced chemotaxis, showing efficacy in CXCR2-overexpressing cells and human neutrophils. In vivo, CX4338 significantly reduced LPS-induced neutrophil numbers in mouse bronchoalveolar lavage fluid. The mechanism of action of CX4338 is to selectively inhibit CXCR2-mediated β-arrestin-2 activation, which is sufficient to inhibit CXCL8-mediated chemotaxis .

HY-15724R

Vercirnon (Standard) GSK-1605786 (Standard); CCX282-B (Standard); Traficet-EN (Standard)	CCR Reference Standards	Inflammation/Immunology Endocrinology
Vercirnon (Standard) is the analytical standard of Vercirnon. This product is intended for research and analytical applications. Vercirnon (GSK1605786A) is an orally bioavailable, selective, and potent antagonist of CCR9. Vercirnon inhibits CCR9-mediated Ca2+ mobilization and chemotaxis on Molt-4 cells with IC50 values of 5.4 and 3.4 nM, respectively. Vercirnon is selective for CCR9 over CCR1-12 and CX3CR1-7 (IC50s>10 μM for all). Vercirnon is an equipotent inhibitor of CCL25-directed chemotaxis of both splice forms of CCR9 (CCR9A and CCR9B) with IC50 values of 2.8 and 2.6 nM, respectively .

HY-15724AR

Vercirnon sodium (Standard) GSK-1605786 sodium (Standard); CCX282-B sodium (Standard); Traficet-EN sodium (Standard)	CCR Reference Standards	Inflammation/Immunology Endocrinology
Vercirnon (sodium) (Standard) is the analytical standard of Vercirnon (sodium). This product is intended for research and analytical applications. Vercirnon (GSK1605786A) sodium is an orally bioavailable, selective, and potent antagonist of CCR9. Vercirnon sodium inhibits CCR9-mediated Ca2+ mobilization and chemotaxis on Molt-4 cells with IC50 values of 5.4 and 3.4 nM, respectively. Vercirnon sodium is selective for CCR9 over CCR1-12 and CX3CR1-7 (IC50s>10 μM for all). Vercirnon sodium is an equipotent inhibitor of CCL25-directed chemotaxis of both splice forms of CCR9 (CCR9A and CCR9B) with IC50 values of 2.8 and 2.6 nM, respectively .

HY-B0019

Azasetron (Rac)-SENS-401 free base	5-HT Receptor	Neurological Disease
Azasetron ((Rac)-SENS-401 free base) is an antiemetic drug with 5-HT3 receptor antagonist activity. Azasetron is often used as a preventive measure for postoperative nausea and vomiting or chemotherapy-induced nausea and vomiting. Azasetron does not impair neutrophil chemotaxis or phagocytosis and does not scavenge O(-)(2) or H(2)O(2) generated by cell-free systems .

HY-N0634R

Cimifugin (Standard) Cimitin (Standard)	Reference Standards NF-κB	Inflammation/Immunology
Cimifugin (Standard) is the analytical standard of Cimifugin. This product is intended for research and analytical applications. Cimifugin (Cimitin) is a bioactive component of Cimicifuga racemosa, a Chinese herb. Cimifugin suppresses allergic inflammation by reducing epithelial derived initiative key factors via regulating tight junctions . Cimifugin reduces the migration and chemotaxis of RAW264.7 cells and inhibits the release of inflammatory factors and activation of MAPKs and NF-κB signaling pathways induced by LPS .

HY-W339833

1-Myristoyl-2-hydroxy-sn-glycero-3-phosphate sodium	Biochemical Assay Reagents
1-Myristoyl-2-hydroxy-sn-glycero-3-phosphate sodium is a kind of activity that promotes platelet aggregation and stimulates smooth muscle contraction. 1-Myristoyl-2-hydroxy-sn-glycero-3-phosphate sodium can enhance cell chemotaxis and cytoskeletal rearrangement. 1-Myristoyl-2-hydroxy-sn-glycero-3-phosphate sodium can also promote Ca2+ mobilization and neurotransmitter release. 1-Myristoyl-2-hydroxy-sn-glycero-3-phosphate sodium also has a certain effect on cell proliferation.

HY-111198

YM-355179 fumarate	Endogenous Metabolite	Inflammation/Immunology
YM-355179 fumarate is a newly synthesized selective CCR3 antagonist with the potential to inhibit eosinophil-related allergic inflammatory diseases. YM-355179 can effectively inhibit the binding of CCL11 and CCL5 to CCR3-expressing cells, with IC₅₀ values of 7.6 nM and 24 nM respectively. In functional experiments, YM-355179 can inhibit CCL11-induced intracellular Ca(2+) influx, chemotaxis and eosinophil degranulation, IC₅₀ The values are 8.0 nM, 24 nM and 29 nM respectively .

HY-W777959

Azasetron Hydrochloride-13C,d3	Isotope-Labeled Compounds 5-HT Receptor	Neurological Disease
Azasetron Hydrochloride- ¹³C,d₃ is the deuterium and ¹³C-labeled Azasetron (HY-B0019). Azasetron ((Rac)-SENS-401 free base) is an antiemetic drug with 5-HT3 receptor antagonist activity. Azasetron is often used as a preventive measure for postoperative nausea and vomiting or chemotherapy-induced nausea and vomiting. Azasetron does not impair neutrophil chemotaxis or phagocytosis and does not scavenge O(-)(2) or H(2)O(2) generated by cell-free systems .

HY-115702S

1-Palmityl-2-O-acetyl-3-glyceryl phosphorylcholine-d4 (Rac)-PAF (C16)-d₄	Isotope-Labeled Compounds Endogenous Metabolite Platelet-activating Factor Receptor (PAFR)	Inflammation/Immunology
1-Palmityl-2-O-acetyl-3-glyceryl phosphorylcholine-d₄ ((Rac)-PAF (C16)-d₄) is the deuterium labeled 1-Palmityl-2-O-acetyl-3-glyceryl phosphorylcholine. 1-Palmityl-2-O-acetyl-3-glyceryl phosphorylcholine is an endogenous inflammatory lipid mediator. 1-Palmityl-2-O-acetyl-3-glyceryl phosphorylcholine acts as a high-affinity agonist for PAFR (GPCR), inducing platelet aggregation, vascular permeability, and leukocyte chemotaxis at extremely low concentrations. 1-Palmityl-2-O-acetyl-3-glyceryl phosphorylcholine exerts its effects via cell surface receptors to regulate inflammation .

HY-B0202S3

Irbesartan-d7 SR-47436-d₇; BMS-186295-d₇	Apoptosis Angiotensin Receptor Isotope-Labeled Compounds	Cardiovascular Disease Endocrinology
Irbesartan-d₇ is deuterated labeled Irbesartan (HY-B0202). Irbesartan (SR-47436) is an orally active Ang II type 1 (AT1) receptor blocker (ARB). Irbesartan can relax the blood vessels, low blood pressure and increase the supply of blood and oxygen to the heart. Irbesartan can be used for the research of high blood pressure, heart failure, and diabetic kidney disease .

HY-B0202AS

Irbesartan-d7 hydrochloride SR-47436-d7 hydrochloride; BMS-186295-d7 hydrochloride	Apoptosis Angiotensin Receptor Isotope-Labeled Compounds	Neurological Disease Metabolic Disease
Irbesartan-d₇ hydrochloride is deuterated labeled Irbesartan hydrochloride (HY-B0202A). Irbesartan (SR-47436) hydrochloride is an orally active Ang II type 1 (AT1) receptor blocker (ARB). Irbesartan hydrochloride can relax the blood vessels, low blood pressure and increase the supply of blood and oxygen to the heart. Irbesartan hydrochloride can be used for the research of high blood pressure, heart failure, and diabetic kidney disease .

HY-103472R

FPR-A14 (Standard)	Reference Standards Formyl Peptide Receptor (FPR)	Neurological Disease
FPR-A14 (Standard) is the analytical standard of FPR-A14 (HY-103472). This product is intended for research and analytical applications. FPR-A14 is a potent formyl peptide receptor (FPR) agonist. FPR-A14 is a potent activator of neutrophil Ca2+ mobilization and chemotaxis with EC₅₀s of 630 nM and 42 nM, respectively. FPR-A14 induces cell differentiation .

HY-164630

CCR5/CXCR3-IN-1	CCR CXCR	Inflammation/Immunology
CCR5/CXCR3-IN-1 (compound 1) is a CXCR3 and CCR5 inhibitor. CCR5/CXCR3-IN-1 inhibits chemotaxis of CXCR3 and CCR5-expressing transformed cells, and does not inhibits the chemotaxis of transfected cells expressing CXCR4. CCR5/CXCR3-IN-1 can be used for the study of chronic arthritic rheumatism .

HY-182564

ST45177901	CCR	Cancer
ST45177901 is a CC chemokine receptor 4 (CCR4) antagonist. The combination of ST45177901 and Sorafenib (HY-10201) effectively inhibits the chemotaxis of Treg cells via the CCL22/CCL17-CCR4 signaling pathway, thereby significantly suppressing the growth and metastasis of tumor cells. ST45177901 is applicable to liver cancer research .

Cat. No.	Product Name	Type

HY-W127575

Cholesta-3,5-diene

delta-3,5-Cholestadiene

Biochemical Assay Reagents

Cholesta-3,5-diene is an inflammatory modulator that targets immune cells such as neutrophils and accelerates wound healing by promoting neutrophil chemotaxis and fibroblast migration. Cholesta-3,5-diene enhances immune cell recruitment and extracellular matrix deposition by activating chemokine receptor-mediated signaling pathways such as PI3K/Akt. Cholesta-3,5-diene can be applied topically to wound repair and has potential therapeutic value in chronic ulcers or skin lesions .

HY-W339833

1-Myristoyl-2-hydroxy-sn-glycero-3-phosphate sodium

Biochemical Assay Reagents

1-Myristoyl-2-hydroxy-sn-glycero-3-phosphate sodium is a kind of activity that promotes platelet aggregation and stimulates smooth muscle contraction. 1-Myristoyl-2-hydroxy-sn-glycero-3-phosphate sodium can enhance cell chemotaxis and cytoskeletal rearrangement. 1-Myristoyl-2-hydroxy-sn-glycero-3-phosphate sodium can also promote Ca2+ mobilization and neurotransmitter release. 1-Myristoyl-2-hydroxy-sn-glycero-3-phosphate sodium also has a certain effect on cell proliferation.

Cat. No.	Product Name	Target	Research Area

HY-P4744

LL-37 amide 2 Publications Verification	Formyl Peptide Receptor (FPR) Bacterial	Infection Cancer
LL-37 amide is a selective agonist of formyl peptide receptor-like FPRL1, effectively inhibiting periodontal pathogens (ED₉₉=8.5-8.7 μg/mL). LL-37 amide exerts its bactericidal effect by activating FPRL1-mediated immune cell chemotaxis and disrupting bacterial cell membrane integrity. It can also regulate inflammatory responses (inhibiting the release of factors such as TNF-α) and promote angiogenesis. Amidation modification reduces its sensitivity to serum inhibition and improves its stability. LL-37 amide possesses key activities in bactericidal action, immunomodulation, and wound healing, and is mainly used in research on infection-related diseases such as periodontal disease and deep tissue injuries (pressure ulcers), and wound healing .

HY-P10724

fMIFL	Formyl Peptide Receptor (FPR) Bacterial	Infection
fMIFL is a formyl tetrapeptide derived from Staphylococcus aureus, and also an agonist of mouse formyl peptide receptor 1 (mFPR1). It exhibits nanomolar activity against mFPR1 and micromolar activity against mFPR2. fMIFL is applicable to studies related to bacterial infections .

HY-P4744A

LL-37 amide TFA 2 Publications Verification	Formyl Peptide Receptor (FPR) Bacterial	Infection Cancer
LL-37 amide TFA is a selective agonist of formyl peptide receptor-like FPRL1, effectively inhibiting periodontal pathogens (ED₉₉=8.5-8.7 μg/mL). LL-37 amide TFA exerts its bactericidal effect by activating FPRL1-mediated immune cell chemotaxis and disrupting bacterial cell membrane integrity. It can also regulate inflammatory responses (inhibiting the release of factors such as TNF-α) and promote angiogenesis. Amidation modification reduces its sensitivity to serum inhibition and improves its stability. LL-37 amide TFA possesses key activities in bactericidal action, immunomodulation, and wound healing, and is mainly used in research on infection-related diseases such as periodontal disease and deep tissue injuries (pressure ulcers), and wound healing .

HY-P11553

ECL1i	CCR	Inflammation/Immunology
ECL1i is an allosteric, selective CCR2 inhibitor. ECL1i specifically inhibits CCL2-/CCR2-mediated chemotaxis. ECL1i interferes with CCR2-positive cell recruitment and attenuates disease progression in experimental autoimmune encephalomyelitis .

HY-P11553A

ECL1i TFA	CCR	Infection Inflammation/Immunology
ECL1i TFA is an allosteric, selective CCR2 inhibitor. ECL1i TFA specifically inhibits CCL2-/CCR2-mediated chemotaxis. ECL1i TFA interferes with CCR2-positive cell recruitment and attenuates disease progression in experimental autoimmune encephalomyelitis .

HY-P1121

WKYMVM-NH2	Formyl Peptide Receptor (FPR)	Inflammation/Immunology
WKYMVM-NH2 is a hexapeptide that activates neutrophils and myeloid cells via the FPRL1 and FPRL2 receptors. It exhibits EC₅₀ values of 2 nM and 80 nM in HL-60-FPRL1 and HL-60-FPRL2 cells, respectively. In HL-60 cells stably expressing FPRL2, WKYMVM-NH₂ induces chemotaxis, with optimal migration observed at concentrations ranging from 10 to 50 nM. It also stimulates superoxide production in neutrophils, with an EC₅₀ of 75 nM. WKYMVM-NH₂ is a useful tool for research in the field of inflammatory diseases .

Cat. No.	Product Name	Target	Research Area	Image

HY-P991567

VX5 VX5/5261	CXCR	Inflammation/Immunology Cancer
VX5 (VX5/5261) is a humanized IgG1κ monoclonal antibody inhibitor targeting BCA-1/CXCL13. VX5 significantly inhibits human CXCL13-mediated internalization of CXCR5, blocks both human and mouse CXCL13-dependent B-cells chemotaxis and migration. VX5 can be used to study autoimmune diseases like multiple sclerosis and arthritis, and cancers like gastric lymphomas and colon cancer .

HY-P99443

Aselizumab HuDreg-55	P-selectin	Inflammation/Immunology
Aselizumab (HuDreg-55) is an humanized IgG4 mAb against L-selectin. However, L-selectin (CD62L) is a cell adhesion molecule expressed on circulating neutrophils. It regulates migrating cells to chemotaxis towards the site of injury. Aselizumab may be account for a high rate of infections and leucopenia after truma .

HY-P992439

PF-06747143	CXCR	Cancer
PF-06747143 is recombinant anti-human antibody targeting CXCR4. PF-06747143 blocks CXCL12-induced calcium flux, F-actin polymerization, chemotaxis, cell migration, and leukemic cell bone marrow homing. PF-06747143 reduces tumor burden and improves survival in mouse models of hematologic malignancies. PF-06747143 can be used for the research of chronic lymphocytic leukemia, acute myeloid leukemia, and hematologic malignancies .

HY-P991944

ZL-1218	CCR	Cancer
ZL-1218 is a selective humanized IgG1 antibody, targeting CCR8. ZL-1218 induces antibody-dependent cellular cytotoxicity (ADCC), leading to NK cell-mediated depletion of CCR8-expressing regulatory T cells (Tregs). ZL-1218 blocks the binding of the CCR8 ligand CCL1 to CCR8 and reduces Treg recruitment by inhibiting the chemotaxis of CCR8 ⁺ cells. ZL-1218 reduces intratumoral Treg levels in a dose-dependent manner. ZL-1218 exerts enhanced antitumor activity when combined with the anti-PD-1 antibody. ZL-1218 can be used for solid tumour research .

HY-P992365

HFB101110	CCR	Cancer
HFB101110 is a human-derived inhibitor and Treg depleter that specifically targets CCR8. It does not bind to the homologous CCR4 receptor and is mainly used in research on solid tumors, renal cell carcinoma and colorectal cancer. HFB101110 blocks hCCL1 binding by interacting with the N-terminal extracellular domain of hCCR8, thereby inhibiting hCCL1-induced calcium influx, chemotaxis and downstream signaling pathways. Meanwhile, HFB101110 can mediate ADCC effects to specifically deplete CCR8-positive cells, including intratumoral Tregs. HFB101110 exhibits favorable anti-tumor activity and pharmacokinetic properties .

Cat. No.	Product Name	Category	Target	Chemical Structure

HY-B2176R

ATP (Standard) Adenosine 5'-triphosphate (Standard)	Structural Classification Alkaloids Human Gut Microbiota Metabolites Microorganisms other families Animals Other Alkaloids Plants Endogenous metabolite Source Classification	Reference Standards Endogenous Metabolite
ATP (Standard) is the analytical standard of ATP. This product is intended for research and analytical applications. ATP (Adenosine 5'-triphosphate) is a central component of energy storage and metabolism in vivo. ATP provides the metabolic energy to drive metabolic pumps and serves as a coenzyme in cells. ATP is an important endogenous signaling molecule in immunity and inflammation . In Vitro: ATP (5 mM; 1 hour) co-treatment with LPS (1 μg/mL) has a synergistic effect on the activation of the NLRP3 inflammasome in HGFs . ATP (2 mM; 0.5-24 hours) induces secretion of IL-1β, KC and MIP-2 from BMDMs in a caspase-1 activation-dependent manner . ATP promotes neutrophil chemotaxis in vitro . In Vivo: ATP (50 mg/kg; i.p.) protects mice against bacterial infection in vivo . ATP induces the secretion of IL-1β, KC and MIP-2 and neutrophils recruitment in vivo .

HY-N0634

Cimifugin 1 Publications Verification Cimitin	Classification of Application Fields Ranunculaceae Coumarins Phenylpropanoids Plants Cimicifuga racemosa (L.) Nutt. Inflammation/Immunology Disease Research Fields	NF-κB
Cimifugin (Cimitin) is a bioactive component of Cimicifuga racemosa, a Chinese herb. Cimifugin suppresses allergic inflammation by reducing epithelial derived initiative key factors via regulating tight junctions . Cimifugin reduces the migration and chemotaxis of RAW264.7 cells and inhibits the release of inflammatory factors and activation of MAPKs and NF-κB signaling pathways induced by LPS .

HY-N0634R

Cimifugin (Standard) Cimitin (Standard)	Structural Classification Ranunculaceae Coumarins Phenylpropanoids Plants Cimicifuga racemosa (L.) Nutt.	Reference Standards NF-κB
Cimifugin (Standard) is the analytical standard of Cimifugin. This product is intended for research and analytical applications. Cimifugin (Cimitin) is a bioactive component of Cimicifuga racemosa, a Chinese herb. Cimifugin suppresses allergic inflammation by reducing epithelial derived initiative key factors via regulating tight junctions . Cimifugin reduces the migration and chemotaxis of RAW264.7 cells and inhibits the release of inflammatory factors and activation of MAPKs and NF-κB signaling pathways induced by LPS .

Cat. No.	Product Name	Chemical Structure

HY-W777959

Azasetron Hydrochloride-13C,d3

Azasetron Hydrochloride- ¹³C,d₃ is the deuterium and ¹³C-labeled Azasetron (HY-B0019). Azasetron ((Rac)-SENS-401 free base) is an antiemetic drug with 5-HT3 receptor antagonist activity. Azasetron is often used as a preventive measure for postoperative nausea and vomiting or chemotherapy-induced nausea and vomiting. Azasetron does not impair neutrophil chemotaxis or phagocytosis and does not scavenge O(-)(2) or H(2)O(2) generated by cell-free systems .

HY-115702S

1-Palmityl-2-O-acetyl-3-glyceryl phosphorylcholine-d4

1-Palmityl-2-O-acetyl-3-glyceryl phosphorylcholine-d₄ ((Rac)-PAF (C16)-d₄) is the deuterium labeled 1-Palmityl-2-O-acetyl-3-glyceryl phosphorylcholine. 1-Palmityl-2-O-acetyl-3-glyceryl phosphorylcholine is an endogenous inflammatory lipid mediator. 1-Palmityl-2-O-acetyl-3-glyceryl phosphorylcholine acts as a high-affinity agonist for PAFR (GPCR), inducing platelet aggregation, vascular permeability, and leukocyte chemotaxis at extremely low concentrations. 1-Palmityl-2-O-acetyl-3-glyceryl phosphorylcholine exerts its effects via cell surface receptors to regulate inflammation .

HY-B0202S3

Irbesartan-d7
Irbesartan-d₇ is deuterated labeled Irbesartan (HY-B0202). Irbesartan (SR-47436) is an orally active Ang II type 1 (AT1) receptor blocker (ARB). Irbesartan can relax the blood vessels, low blood pressure and increase the supply of blood and oxygen to the heart. Irbesartan can be used for the research of high blood pressure, heart failure, and diabetic kidney disease .

HY-B0202AS

Irbesartan-d7 hydrochloride

Irbesartan-d₇ hydrochloride is deuterated labeled Irbesartan hydrochloride (HY-B0202A). Irbesartan (SR-47436) hydrochloride is an orally active Ang II type 1 (AT1) receptor blocker (ARB). Irbesartan hydrochloride can relax the blood vessels, low blood pressure and increase the supply of blood and oxygen to the heart. Irbesartan hydrochloride can be used for the research of high blood pressure, heart failure, and diabetic kidney disease .

Cat. No.	Product Name		Classification

HY-174761

Human CCL21 mRNA		mRNA Chemokine & Receptors
Human CCL21 mRNA encodes the human C-C motif chemokine ligand 21 (CCL21) protein, a chemokine that can inhibit hemopoiesis and stimulate chemotaxis. CCL21 is chemotactic in vitro for thymocytes and activated T cells, but not for B cells, macrophages, or neutrophils. It may also play a role in mediating homing of lymphocytes to secondary lymphoid organs.

HY-W783254

C18 LPA PA(18:0e/0:0)		Phospholipids
C18 LPA (PA(18:0e/0:0)) is a water-soluble phospholipid that functions as a signaling molecule, influencing various cellular responses through G protein-coupled receptors (GPCRs). It is known to promote smooth muscle contraction, cytoskeletal rearrangement, and chemotaxis, while also playing a role in neurotransmitter release, cell proliferation, platelet aggregation, and Ca2+ mobilization. Elevated levels of C18 LPA in human plasma are associated with ovarian cancer and atherosclerosis, suggesting its potential as a biomarker for ovarian cancer.

HY-174553

Human PDGFA mRNA		mRNA
Human PDGFA mRNA encodes the human platelet derived growth factor A (PDGFA) protein, a member of the platelet-derived growth factor family. PDGFA plays an essential role in the regulation of embryonic development, cell proliferation, cell migration, survival and chemotaxis.

HY-174552

Human PDGFB mRNA		mRNA
Human PDGFB mRNA encodes the human platelet derived growth factor B (PDGFB) protein, a member of the platelet-derived growth factor family. PDGFB plays an essential role in the regulation of embryonic development, cell proliferation, cell migration, survival and chemotaxis.

HY-174550

Human PDGFD mRNA		mRNA
Human PDGFD mRNA encodes the human platelet derived growth factor D (PDGFD) protein, a member of the platelet-derived growth factor family. PDGFD plays an essential role in the regulation of embryonic development, cell proliferation, cell migration, survival and chemotaxis.

HY-174551

Human PDGFC mRNA		mRNA
Human PDGFC mRNA encodes the human platelet derived growth factor C (PDGFC) protein, a member of the platelet-derived growth factor family. PDGFC plays an essential role in the regulation of embryonic development, cell proliferation, cell migration, survival and chemotaxis.

HY-174752

Human CCL4L1 mRNA		mRNA Chemokine & Receptors
Human CCL4L1 mRNA encodes the human C-C motif chemokine ligand 4 like 1 (CCL4L1) protein, a chemokine that can induce chemotaxis of cells expressing CCR5 or CCR1.

HY-174741

Human CCR8 mRNA		mRNA Chemokine & Receptors
Human CCR8 mRNA encodes the human C-C motif chemokine receptor 8 (CCR8) protein, a member of the beta chemokine receptor family. CCR8 plays a role in regulation of monocyte chemotaxis and thymic cell apoptosis. More specifically, this receptor may contribute to the proper positioning of activated T cells within the antigenic challenge sites and specialized areas of lymphoid tissues.

Inquiry Online

Your information is safe with us. * Required Fields.

MCE Japan Authorized Agent ナミキ商事株式会社コスモ・バイオ株式会社重松貿易株式会社
Salutation			Country or Region *
Applicant Name *			Organization Name *
Department *
Email Address *			Product Name *
Cat. No.			Requested quantity *
Phone Number *
Remarks

Inquiry Online

Inquiry Information

Product Name:
Cat. No.:
Quantity:
MCE Japan Authorized Agent:

cell chemotaxis

Inhibitors & Agonists

Biochemical Assay Reagents

Peptides

Inhibitory Antibodies

NaturalProducts

Isotope-Labeled Compounds

Oligonucleotides

Natural
Products